title: Intra-arterial thrombolysis of central retinal artery occlusion following percutaneous atrial septal defect closure.
abstract: Use of percutaneous devices for atrial septal defect (ASD) closure is growing, given the minimally invasive nature and the long-term durability of this approach. The reported rate of thrombus formation after catheter closure is 1.2%. Thrombotic risk varies according to closure device and Dacron-covered nitinol Amplatzer devices carry a 0-0.3% rate of thrombus formation; but central retinal artery occlusion (CRAO) is rarely implicated as an adverse event. Herein, we report the first successful intra-arterial thrombolytic treatment of CRAO developing after ASD closure via Amplatzer device. © 2015 Wiley Periodicals, Inc.
authors.affiliation: Department of Neurosurgery, Hallym University College of Medicine, Chuncheon, Korea.
authors.forename: Jin Pyeong
authors.initials: JP
authors.lastname: Jeon
authors.affiliation: Department of Radiology, Seoul National University College of Medicine, Seoul, Korea.
authors.forename: Young Dae
authors.initials: YD
authors.lastname: Cho
authors.affiliation: Department of Radiology, Seoul National University College of Medicine, Seoul, Korea.
authors.forename: Moon Hee
authors.initials: MH
authors.lastname: Han
mesh_terms: D006328:Cardiac Catheterization / Q000009:adverse effects* / Q000295:instrumentation; D002533:Cerebral Angiography; D038524:Diffusion Magnetic Resonance Imaging; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage*; D006344:Heart Septal Defects, Atrial / Q000000981:diagnostic imaging / Q000628:therapy*; D006801:Humans; D007261:Infusions, Intra-Arterial; D020127:Recovery of Function; D012039:Regional Blood Flow; D015356:Retinal Artery Occlusion / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D055989:Septal Occluder Device; D015912:Thrombolytic Therapy; D013927:Thrombosis / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D016896:Treatment Outcome; D014568:Urokinase-Type Plasminogen Activator / Q000008:administration & dosage*; D014786:Vision Disorders / Q000209:etiology / Q000503:physiopathology; D014785:Vision, Ocular; D014792:Visual Acuity; D055815:Young Adult
chemical_list: D005343:Fibrinolytic Agents; D014568:Urokinase-Type Plasminogen Activator
keywords: atrial septal defect; central retinal artery occlusion; thrombolysis